Dietary arginine restriction with chemoradiation for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether limiting an amino acid called arginine in the diet, along with standard chemoradiation before surgery, can improve treatment outcomes for people with locally advanced rectal cancer. It aims to make the cancer more responsive to treatment and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with locally advanced rectal cancer that has not spread to distant organs (stage II or III).
- You are in good overall health, with a performance status of 0 or 1 (able to carry out daily activities).
- You are well-nourished, with a body mass index (BMI) of at least 18.5 and no significant weight loss or malnutrition.
- You can eat by mouth or use a feeding tube, and your organ functions (liver, kidneys, blood counts) are within acceptable ranges.
- You are not pregnant or breastfeeding, and you agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special diet low in two amino acids (serine and glycine) can make standard chemotherapy and radiation more effective for rectal cancer. It aims to see if this dietary change helps shrink tumors and reduce side effects.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests a new combination of standard chemotherapy, immunotherapy (a drug that helps your immune system fight cancer), and a special diet and/or high-dose vitamin C before surgery for rectal cancer. It aims to shrink the tumor and improve surgery outcomes.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
Hear when a new Rectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.